(Q33876245)

29 July 2017

1 reference

title

Carbapenems in serious infections: a risk-benefit assessment (English)

1 reference

29 July 2017

main subject

carbapenem antibiotic

0 references

author name string

S R Norrby

series ordinal

1

1 reference

29 July 2017

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

191-194

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200022030-00003

29 July 2017

exact match

0 references

cites work

Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997)

1 reference

12 December 2020

Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group

1 reference

12 December 2020

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

1 reference

12 December 2020

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

1 reference

12 December 2020

Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin

1 reference

12 December 2020

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

12 December 2020

Thienamycin: development of imipenen-cilastatin

1 reference

12 December 2020

A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

1 reference

12 December 2020

Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats

1 reference

12 December 2020

Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group

1 reference

12 December 2020

In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group

1 reference

12 December 2020

Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network

1 reference

12 December 2020

Neurotoxicity of benzylpenicfllin: correlation to concentrations in serum, cerebrospinal fluid and brain tissue fluid in rabbits

1 reference

12 December 2020

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

1 reference

12 December 2020

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

12 December 2020

Neurotoxicity of carbapenem antibacterials

1 reference

12 December 2020

Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem

1 reference

12 December 2020

Imipenem/cilastatin: rationale for a fixed combination

1 reference

12 December 2020

Imipenem/cilastatin treatment of bacterial meningitis in children

1 reference

12 December 2020

10.2165/00002018-200022030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1037510502

0 references

1 reference